Canagliflozin vs Zibotentan + Dapagliflozin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Kidney Disease

Shared mechanism: SGLT2 · full Chronic Kidney Disease pipeline

Canagliflozin · Invokana

Marketed by Johnson & Johnson and partners

Approved in Chronic Kidney Diseasesmall molecule
Reliable signal

NCT02065791 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial in 4,401 participants with type 2 diabetes and diabetic nephropathy. Canagliflozin significantly lowered the rate of the composite renal/cardiovascular endpoint (kidney failure, doubling of creatinine, or renal/CV death) compared with placebo, with a hazard ratio of 0.70.

Next expected readout: December 2026 · NCT05507892 (registry estimate)

Reported efficacy

Percentage of Participants With 30% Decline in Estimated Glomerular Filtration Rate (eGFR) From Baseline at Week 104: Incidence of 30% eGFR decline at week 104: 18.2% canagliflozin vs 29.5% placebo; intergroup difference (placebo-canagliflozin) 11.3% (95% CI 1.2-21.5, P=0.029) (met)

Result source: NCT03436693

Zibotentan + Dapagliflozin

Developed by AstraZeneca

Phase 3 in Chronic Kidney Diseasesmall molecule (combination)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: February 2027 · NCT06087835 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Chronic Kidney Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCanagliflozinZibotentan + Dapagliflozin
Kidney composite outcome—Not reported—Trial running · NCT06087835
UACR, % change0.6% vs 1.2%−0.6 vs placebo100mg · wk 104 · n 124NCT03436693—Trial running · NCT06087835
eGFR slope—Not reported—Trial running · NCT06087835
Haemoglobin, change—Not reported—Trial running · NCT06087835

Kidney composite outcome

Canagliflozin
—Not reported
Zibotentan + Dapagliflozin
—Trial running · NCT06087835

UACR, % change

Canagliflozin
0.6% vs 1.2%−0.6 vs placebo100mg · wk 104 · n 124NCT03436693
Zibotentan + Dapagliflozin
—Trial running · NCT06087835

eGFR slope

Canagliflozin
—Not reported
Zibotentan + Dapagliflozin
—Trial running · NCT06087835

Haemoglobin, change

Canagliflozin
—Not reported
Zibotentan + Dapagliflozin
—Trial running · NCT06087835
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Zibotentan + Dapagliflozin: registry results are on file for Chronic Kidney Disease, but their comparison mappings are not yet available.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Canagliflozin: 4 of 4 rows · Zibotentan + Dapagliflozin: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCanagliflozin
Dropout rate
0.7%100 mga
NCT02065791 · Phase 3
show 1 more result
19.5%100mg
NCT03436693 · Phase 3
Discontinued due to AEs
—100 mga
NCT02065791 · Phase 3
show 1 more result
14.3%100mg
NCT03436693 · Phase 3
Serious AEs
33.5%100 mga
NCT02065791 · Phase 3
show 1 more result
27.9%100mg
NCT03436693 · Phase 3
Most frequent reported AEs
100 mga
hypoglycaemia 9.7% (placebo 10.3%)
urinary tract infection 9.2% (placebo 8.4%)
hypertension 6.5% (placebo 8.8%)
NCT02065791 · Phase 3
show 1 more result
100mg
nasopharyngitis 35.1% (placebo 37%)
hypoglycaemia 21.4% (placebo 20.8%)
blood glucose decreased 17.5% (placebo 14.9%)
NCT03436693 · Phase 3

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Canagliflozin

eGFR 30% Decline 18.2% (n=154) vs 29.5% (n=154) placebo @ 104wk100mg
responder rate · % of participants
NCT03436693 · Phase 3
eGFR 40% Decline 10.1% (n=154) vs 13.9% (n=154) placebo @ 104wk100mg
responder rate · % of participants
NCT03436693 · Phase 3
eGFR Change mL/Min/1.73 m2 -10.39 vs -11.49 placebo mL @ 104wk100mg
absolute change · mL
NCT03436693 · Phase 3
UACR 0.612% (n=124) vs 1.178% (n=127) placebo @ 104wk100mg
percent change · % of baseline
NCT03436693 · Phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Canagliflozin's landscape · Zibotentan + Dapagliflozin's landscape